Technical Analysis for AGIO - Agios Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Oversold Stochastic | Weakness | 0.00% | |
Bullish Engulfing | Bullish | -2.17% | |
Pocket Pivot | Bullish Swing Setup | -2.17% | |
Multiple of Ten Bearish | Other | -2.17% | |
Oversold Stochastic | Weakness | -2.17% | |
Stochastic Reached Oversold | Weakness | -0.58% | |
Wide Bands | Range Expansion | -0.58% | |
Down 3 Days in a Row | Weakness | -0.58% | |
Down 4 Days in a Row | Weakness | -0.58% | |
Down 5 Days in a Row | Weakness | -0.58% |
Alert | Time |
---|---|
Down 3% | about 21 hours ago |
Fell Below Previous Day's Low | about 21 hours ago |
Down 2 % | about 21 hours ago |
Down 1% | about 22 hours ago |
60 Minute Opening Range Breakout | 4 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/02/2024
Agios Pharmaceuticals, Inc. Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acid Hydrogen Metabolism Organic Chemistry Glutamate Inborn Errors Of Metabolism Pyruvate Kinase Deficiency
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 35.5 |
52 Week Low | 19.795 |
Average Volume | 858,026 |
200-Day Moving Average | 25.18 |
50-Day Moving Average | 26.51 |
20-Day Moving Average | 31.02 |
10-Day Moving Average | 30.56 |
Average True Range | 1.28 |
RSI (14) | 49.75 |
ADX | 41.07 |
+DI | 24.72 |
-DI | 19.62 |
Chandelier Exit (Long, 3 ATRs) | 31.66 |
Chandelier Exit (Short, 3 ATRs) | 28.72 |
Upper Bollinger Bands | 34.95 |
Lower Bollinger Band | 27.09 |
Percent B (%b) | 0.28 |
BandWidth | 25.32 |
MACD Line | 0.90 |
MACD Signal Line | 1.48 |
MACD Histogram | -0.5718 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 30.88 | ||||
Resistance 3 (R3) | 30.94 | 30.47 | 30.62 | ||
Resistance 2 (R2) | 30.47 | 30.07 | 30.44 | 30.53 | |
Resistance 1 (R1) | 29.88 | 29.81 | 29.65 | 29.82 | 30.44 |
Pivot Point | 29.41 | 29.41 | 29.29 | 29.38 | 29.41 |
Support 1 (S1) | 28.82 | 29.01 | 28.59 | 28.76 | 28.14 |
Support 2 (S2) | 28.35 | 28.75 | 28.32 | 28.05 | |
Support 3 (S3) | 27.76 | 28.35 | 27.97 | ||
Support 4 (S4) | 27.70 |